Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

NCT04471974 is registered in ClinicalTrials.gov with Rahul Aggarwal as lead sponsor.

NCT NCT04471974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04471974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
Lead sponsor
Rahul Aggarwal
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 26, 2021
Completion date
May 31, 2028
Enrollment
61 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic prostate adenocarcinoma, metastatic prostate small cell carcinoma, stage iv prostate cancer ajcc v8, stage iva prostate cancer ajcc v8, stage ivb prostate cancer ajcc v8